Table 1.
Summary of demographic and baseline characteristics for FAS
| F-627 | Filgrastim | |
|---|---|---|
| Characteristic a | 20 mg | 5 ug/kg/d |
| Sex, n (%) | ||
| Female | 120 (100) | 119 (100) |
| Age, years | 49.1 (9.32) | 48.5 (9.14) |
| Height, cm | 157.97 (5.06) | 157.87 (5.52) |
| Weight, kg | 58.96 (8.95) | 59.24 (8.49) |
| BSA, m2 | 1.59 (0.12) | 1.59 (0.12) |
| Time from histologic diagnosis to signing ICF, days | 24.5 (18.08) | 20.9 (13.51) |
| ECOG performance status, n (%) | ||
| 0 | 26 (21.7) | 35 (29.4) |
| 1 | 94 (78.3) | 83 (69.7) |
| 2 | 0 (0) | 1 (0.8) |
| TNM stage, n (%) | ||
| Stage I | 30 (25.0) | 30 (25.2) |
| Stage II | 58 (48.3) | 66 (55.5) |
| Stage III | 32 (26.7) | 22 (18.5) |
| Stage IV | 0 (0) | 1 (0.8) |
| Baseline ANC (× 109/L) | 4.4 (1.58) | 4.5 (1.62) |
| Baseline Platelet Count (× 109/L) | 286.9 (72.0) | 284.5 (77.6) |
Abbreviations: ICF Informed Consent Form, ECOG Eastern Cooperative Oncology Group, BSA Body surface area, TNM Tumor node metastasis, ANC Absolute neutrophil count
aMean (SD), unless noted